← Back to Screener
Atrium Therapeutics, Inc. Common Stock (RNA)
Price$11.80
Value ScoreC
Growth ScoreC
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-91.47%
Price vs S&P 500 (4W)-9.71%
VGM Score40.71
Market Capitalization$201.85M
All Metrics
Book Value / Share (Quarterly)$13.69
P/TBV (Annual)0.80x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)58.44%
Cash Flow / Share (Quarterly)$-4.06
Price vs S&P 500 (YTD)-91.80%
Net Profit Margin (TTM)-172.89%
EPS (TTM)$-3.86
10-Day Avg Trading Volume0.22M
EPS Excl Extra (TTM)$-3.86
Revenue Growth (5Y)36.26%
EPS (Annual)$-2.89
ROI (Annual)-35.34%
Net Profit Margin (5Y Avg)-1796.59%
Cash / Share (Quarterly)$15.66
Revenue Growth QoQ (YoY)-71.11%
ROA (Last FY)-592.61%
Revenue Growth TTM (YoY)22.02%
EBITD / Share (TTM)$-3.88
ROE (5Y Avg)-28.11%
Operating Margin (TTM)-174.92%
Cash Flow / Share (Annual)$-2.49
P/B Ratio0.86x
P/B Ratio (Quarterly)0.98x
Net Income / Employee (Annual)$-1,053,200
EV / Revenue (TTM)91.25x
Net Interest Coverage (TTM)-2.35x
ROA (TTM)-33.70%
EPS Growth QoQ (YoY)13.99%
EPS Incl Extra (Annual)$-2.89
Current Ratio (Annual)0.07x
Quick Ratio (Quarterly)12.92x
3-Month Avg Trading Volume1.46M
52-Week Price Return-66.84%
Revenue / Employee (TTM)$813,900
Tangible BV / Share (Quarterly)$6.98
P/S Ratio (Annual)10.84x
Asset Turnover (Annual)2.23x
52-Week High$73.06
Operating Margin (5Y Avg)-1959.94%
EPS Excl Extra (Annual)$-2.89
CapEx CAGR (5Y)96.69%
26-Week Price Return-83.54%
Quick Ratio (Annual)0.03x
13-Week Price Return-23.72%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.04x
Enterprise Value$-66.00M
Revenue / Share Growth (5Y)13.23%
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$396,100
Pretax Margin (Annual)-266.64%
Cash / Share (Annual)$8.75
3-Month Return Std Dev47.39%
Net Income / Employee (TTM)$-1,407,100
ROE (Last FY)-36.27%
EPS Basic Excl Extra (Annual)$-2.89
Receivables Turnover (TTM)19.72x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.86
ROI (TTM)-44.34%
P/S Ratio (TTM)5.28x
Pretax Margin (5Y Avg)-1796.59%
Revenue / Share (Annual)$1.09
Tangible BV / Share (Annual)$8.29
Price vs S&P 500 (52W)-91.21%
EPS Growth TTM (YoY)8.34%
Year-to-Date Return-83.64%
5-Day Price Return-6.94%
EPS Normalized (Annual)$-2.89
ROA (5Y Avg)-24.50%
Net Profit Margin (Annual)-265.88%
Month-to-Date Return-9.23%
Cash Flow / Share (TTM)$-2.93
EBITD / Share (Annual)$-2.88
Operating Margin (Annual)-266.58%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-28.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.86
P/TBV (Quarterly)0.90x
P/B Ratio (Annual)0.76x
Pretax Margin (TTM)-173.26%
Book Value / Share (Annual)$8.29
Price vs S&P 500 (13W)-31.98%
Beta1.03x
P/FCF (Annual)3.60x
Revenue / Share (TTM)$2.24
ROE (TTM)-40.30%
52-Week Low$11.77
vGradeC
gGradeC
mGradeF
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.97est. -1.06
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNAAtrium Therapeutics, Inc. Common Stock | C | C | F | $11.80 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Atrium Therapeutics develops RNA-based therapeutics for genetic forms of cardiomyopathy. The company's proprietary platform uses ligand-based targeting to deliver RNA therapies directly to heart tissue. Current pipeline programs focus on cardiomyopathies associated with PRKAG2 and PLN gene mutations.